GSK: positive phase III results for lupus nephritis drug
(CercleFinance.com) - GSK said a late-stage study showed its intravenous Benlysta drug prompted a clinically meaningful improvement in patients with lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus.
The trial, which enrolled 448 patients, met its primary endpoint, demonstrating that a statistically significant greater number of patients achieved primary efficacy renal response over two years when treated with belimumab plus standard therapy compared to placebo plus standard therapy.
Based on this data, GSK plans to progress regulatory submissions in the first half of 2020, it said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The trial, which enrolled 448 patients, met its primary endpoint, demonstrating that a statistically significant greater number of patients achieved primary efficacy renal response over two years when treated with belimumab plus standard therapy compared to placebo plus standard therapy.
Based on this data, GSK plans to progress regulatory submissions in the first half of 2020, it said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.